The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
|Articles|June 30, 2015
Mining Twitter Hashtags to Find Unknown Drug Issues
A team of scientists at the University of Vermont has invented a new technique for discovering potentially dangerous drug interactions and unknown side-effects using Twitter hashtags.
Advertisement
A team of scientists at the University of Vermont has invented a new technique for discovering potentially dangerous drug interactions and unknown side-effects using Twitter hashtags.
Previous studies have shown that Twitter can be mined for bad drug interactions, but the Vermont team advances this idea by focusing on the distinctive information contained in hashtags-like “#overprescribed,” “#kidneystoneprobs,” and “#skinswelling”-to find new associations. The overall goal of the project, supported by the National Science Foundation, was to discover is to discover any relationship between two drugs that is not known.
Using their new algorithm, the team has created a website that will allow an investigator to explore the connections between search terms (say "albuterol"), existing scientific studies indexed in PubMed-and Twitter hashtags associated with the terms and studies.
A report on how the algorithm works, and its preliminary discoveries, was published online, June 8, in the Journal of Biomedical Informatics.
Advertisement
Related to this article
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.
The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.
In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without
4
Closing the Medical Writing Capacity Gap: Why Training Beats Technology
5